Literature DB >> 26582242

Effect of Lymph Node Count on Pathological Stage III Rectal Cancer with Preoperative Radiotherapy.

Qingguo Li1,2, Lei Liang1,2, Lu Gan1,3, Guoxiang Cai1,2, Xinxiang Li1,2, Sanjun Cai1,2.   

Abstract

Lymph node (LN) status after surgery for rectal cancer is affected by preoperative radiotherapy. The purpose of this study was to perform a population-based evaluation of the impact of pathologic LN status after neoadjuvant radiotherapy on survival. A total of 1,650 patients receiving neoadjuvant chemotherapy in Surveillance, Epidemiology, and End Results Program (SEER)-registered ypIII stage rectal cancer was analyzed. We identified the optimal cutoff for retrieved LNs as 10 (χ2 = 14.006, P < 0.001), which was validated as an independent prognosis factors in a Cox regression model. Further analysis showed that the LN count was only a prognosis factor with the number from 8 to 16(except for 13).After the number 16, the 5-year survival rate decreased gradually. Collectively, our results confirmed that the number of LNs in yp III stage rectal patients was a prognosis factor only with the numbers from 8 to 16(except for 13). Using the total mesorectal excision technique with an adequate pathologic examination, a large number of LNs retrieved (≥17) might indicate worse tumor response grade and poorer survival.

Entities:  

Mesh:

Year:  2015        PMID: 26582242      PMCID: PMC4652213          DOI: 10.1038/srep16990

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Preoperative radiotherapy (preop-RT) has become part of standard practice offered to improve treatment outcomes in patients with rectal cancer12. According to the guidelines for colorectal cancer from the National Comprehensive Cancer Network (NCCN), a minimum of twelve lymph nodes (LNs) must be retrieved and examined for accurate staging and the number of metastatic LNs was validated as an independent prognostic factors345. Many factors can influence the number of LNs harvested after rectal cancer resection and it has been shown that preop-RT might reduce the number of LNs retrieved67. With the decreased LNs retrieval, the prognostic value of the LN count might also diminish. Increasingly, there is doubt regarding the recommended minimum retrieval of 12 LNs for ypTNM staging8. There have been some studies of the optimal LNs retrieval cutoff in ypN0 patients, but few studies have focused on ypN(+) patients. One possible method of identifying a reasonable cutoff value that allows the reliable staging of rectal cancer with LNs metastases treated with preop-RT is to analyze patient survival in a large series of patients diagnosed as ypN(+). The purpose of this study was to assess the impact of the number of LNs examined on survival of rectal cancer patients treated with preop-RT at ypN(+) stage and to determine the optimal number of LNs that should be examined.

Results

Patient Characteristics in SEER database

In our 8-year study period, a total of 1,650 with rectal cancer met our selection criteria, including 1,042 male and 608 female. The median patient age was 57 years (IQR 48-66). There were 1,125 patients with ypN1 stage and 525 with ypN2 stage. Patient demographics and pathological features are summarized in Table 1. Patients with ypN2 stage had a lower rate of high/moderate grade tumors, a higher proportion of mucinous/signet ring adenocarcinoma, and higher ratios of ypT3/4 tumor stage, which reached the level of significance (p < 0.001).
Table 1

Characteristics of patients included in the study and make comparison between the ypN1 and ypN2 groups.

CharacteristicTotalypN1ypN2P value
(n = 1650) (%)(n = 1125) (%)(n = 525)
Media foullow up(mo)64(2–155)69 (2–155)54(2–153)<0.001
Sex   0.412
male1042718(63.8)324(61.7) 
female608407(36.2.)201 (38.3) 
Age57(20–80)58(20-80)56(21–80)0.059
Race   0.725
White1345921(81.9)424(80.9) 
Black12888(7.8)40(7.6) 
Other177116(10.3)61(11.6) 
Pathological grading   <0.001
High/Moderate1133808(71.8)325(61.9) 
Poor/Anaplastic376216(19.2)160(30.5) 
Unknown141101(9.0)40(7.6) 
Histotype   <0.001
Adenocarcinoma1333955(85.0)378(72.3) 
Mucinous /Signet ring cell313168(15.0)145(27.7) 
T stage   <0.001
Tis54(0.4)1(0.2) 
T1/T2228182(16.2)46(8.8) 
T3/41393920(81.9)473(90.1) 
TX2318(1.6)5(1.0) 
No. of LNs dissected12(1–69)10(1–58)15(4–69)<0.001

Identification of Cutoff points for the minimum number of LNs retrieved in ypN(+) patients in the SEER database

X-tile plots were constructed and the maximum χ2 log-rank value of 14.006 (P < 0.001) was produced, applying 10 as the optimal cutoff value to divide the cohort into high and low risk subsets in terms of rectal cancer cause-specific survival (RCSS) (Fig. 1). To assess the influence of different LN retrieval on RCSS, we analyzed the individual result using different LN number values ranging from 5 to 19. The number below 5 and over 19 weren’t analyzed to guarantee sufficient statistical power. The 5-year RCSSs were calculated for patients with N (LNs number) or more nodes and less than N nodes (Table 2). The number of LNs retrieved was a prognosis factor only for number ranging from 8 to 16 (except for 13, P value = 0.062).The 5-year RCSS of patients with N or more nodes increased gradually when N ranged from 5 to 9 and the result was roughly the same from 10 to 15 peaking to 65.7% at cutoff 11; but after the number 16, the 5-year RCSS gradually decreased.
Figure 1

X-tile analysis of survival data from the SEER registry.

X-tile analysis was performed using patient data, which were equally divided into training and validation sets, from the SEER registry. X-tile plots of the training sets are shown in the left panels, with plots of matched validation sets shown in the smaller inset. The optimal cut-point highlighted by the black circle in the left panels is shown on a histogram of the entire cohort (middle panels), and a Kaplan-Meier plot (right panels). P values were determined using the cutoff point defined in the training set and applying it to the validation set. Figure 1 shows the optimal cutoff point for the ypN (+) patients (10, χ2 = 14.006, P < 0.001).

Table 2

Univariate analysis of the influence of different total lymph node count on RCSS in ypIII stage rectal cancer patients.

Total lymph node countNo.5-year CCSLog-rank χ2P value*
<525058.3%0.8100.368
≥5140061.4%  
<635956.1%3.8710.049
≥6129162.3%  
<745757.8%2.0080.157
≥7119362.1%  
<859355.9%9.6090.002
≥8105763.7%  
<970356.6%11.1640.001
≥994764.1%  
<1078856.6%14.006<0.001
≥1086264.8%  
<1190257.0%13.4920.001
≥1174865.7%  
<1299158.0%8.5150.004
≥1265965.4%  
<13107159.3%3.4740.062
≥1357964.0%  
<14114059.4%4.1270.042
≥1451064.3%  
<15119259.2%4.7710.029
≥1545865.3%  
<16125159.8%3.5810.058
≥1639964.4%  
<17130460.4%2.1650.141
≥1734662.3%  
<18135560.6%1.0580.304
≥1829562.6%  
<19140160.6%1.0570.304
≥1924962.7%  

*P values refer to the log-rank test of the differences between the two survival curves generated using Kaplan-Meier analysis.

Prognostic value of number of LNs retrieved

The number of LNs and other clinicopathological factors, including elderly patients (P < 0.001), black patients (P = 0.043), poor and undifferentiated tumor grades (P < 0.001), mucinous and signet-ring cancer (P = 0.001), advanced TN stages (P < 0.001), higher negative to positive LNs ratio (P < 0.001), and number of LNs (P < 0.001), were significant risk factors for poor survival according to univariate analysis (Table 3). In univariate analysis, age, race, tumor grade, T stage, N stage, higher negative to positive LNs ratio, and LN counts (with an optimal cutoff of 10) were independently and significantly associated with RCSS (Table 3), and a higher number of LNs demonstrated a positive effect on survival (hazard ratio [HR] 0.744; 95% confidence interval [CI] 0.631-0.877, P < 0.001) (Table 3).
Table 3

Univariate and multivariate survival analyses evaluating the number of retrieved LNs influencing RCSS in ypN(+) rectal cancer patients.

Variable Univariate analysisMultivariate analysis
5-year RCCSLog rank χ2testP*HR(95%CI)P
Sex 0.0700.791 NI
Male61.1%    
Female60.7%    
Age 24.963<0.001 <0.001
<6064.6%  Reference 
≥6055.8%  1.439(1.247–1.659) 
Race 6.3110.043 0.016
Caucasian62.1%  Reference 
Black51.4%  1.404(1.095–1.799) 
others59.1%  1.170 (0.931–1.471) 
Grade 57.252<0.001 <0.001
High/ Moderate65.3%  Reference 
Poor/ Anaplastic44.7%  1.657(1.412–1.944) 
Unknown68.5%  0.892(0.672–1.184) 
Histotype 10.8760.001 0.462
Adenocarcinoma62.6%  Reference 
Mucinous/signet ring cell54.5%  1.069(0.895–1.276) 
ypT Stage 22.284<0.001 0.003
Tis60.0%  1.173(0.287–4.792) 
T1-276..2%  Reference 
T3-458.4%  1.565(1.238–1.979) 
Tx60.3%  1.397(0.722–2.704) 
ypN Stage 81.663<0.001 <0.001
ypN167.5%  Reference 
ypN246.7%  1.638(1.358–1.975) 
N/P LNs ratio 90.460<0.001 0.001
≦2.3349.9%  Reference 
>2.3370.6%  0.735(0.631–0.877) 
No. of LNs 14.006<0.001 <0.001
<1056.6%  Reference 
≥1064.8%  0.744(0.631–0.877) 

NI: not included in multivariate survival analysis.

N/P LNs ratio: The ratio of the number of negative lymph nodes to the number of metastatic lymph nodes.

*P values refer to the log-rank test of the differences between the two survival curves generated using Kaplan-Meier analysis.

Subgroup analysis of the effect of LNs retrieved during ypIII stage

According to the AJCC-7 rectal cancer staging system, patients with LNs metastases were all classified as ypIII stage, which included three subgroups (i.e., ypIIIA, ypIIIB, and ypIIIC). We then further analyzed these three subgroups. Patients with ypTis (n = 5) and ypTx (n = 23) were excluded from this analysis. The results showed that the retrieved LNs (with a cutoff of 10) were significantly associated with 5-year RCSS, according to the univariate analysis in the ypIIIB (χ2 = 22.817, P < 0.001) and ypIIIC subgroups (χ2 = 13.225, P < 0.001), but not in the ypIIIA subgroup (χ2 = 0.121, P = 0.728) (Fig. 2, Table 4 and 5, ). The number of LNs retrieved was also validated as an independent survival factor by multivariate Cox regression in the ypIIIB (LNs≥10, HR 0.698, 95% CI 0.552–0.882, P = 0.003) and ypIIIC subgroups (LNs≥10, HR 0.718, 95%CI 0.553–0.933,P = 0.013) (Table 4 and 5, )
Figure 2

Log-rank tests of rectal cancer cause-specific survival comparing patients with ≥10 lymph nodes with patients who had <10 nodes for (a) stage ypIIIA: χ2 = 0.121, P = 0.728; (b) stage ypIIIB: χ2 = 22.817, P < 0.001; and (c) stage ypIIIC: χ2 = 13.225, P < 0.001.

Table 4

Univariate and multivariate survival analyses evaluating the number of retrieved LNs influencing RCSS in ypIIIB rectal cancer patients.

Variable5-year RCCSUnivariate analysisP*Multivariate analysis
Log rank χ2testHR(95% CI)P
Sex 0.5760.448 NI
 Male65.8%    
 Female63.8%    
Age 19.534<0.001 <0.001
 <6069.3%  Reference 
 ≥6059.5%  1.500(1.237–1.820) 
Race 6.5800.037 0.025
 Caucasian66.1%  Reference 
 Black51.8%  1.556(1.131–2.141) 
 others67.9%  1.025(0.731–1.437) 
Grade 34.685<0.001 <0.001
 High/ Moderate69.1%  Reference 
 Poor/ Anaplastic47.8%  1.728(1.388-2.151) 
 Unknown74.2%  0.803(0.536–1.203) 
Histotype 5.1860.023 0.325
 Adenocarcinoma66.5%  Reference 
 Mucinous/signet ring cell58.9%  1.134(0.883–1.455) 
ypT Stage 6.4750.039 0.009
 T1-253.8%  Reference 
 T367.6%  0.973(0.460-2.059) 
 T460.5%  1.364(0.625–2.975) 
ypN Stage 13.788<0.001 0.002
 ypN167.1%  Reference 
 ypN253.6%  1.616(1.195–2.185) 
N/P LNs ratio 27.218<0.001 0.070
 ≦2.3356.1%  Reference 
 >2.3370.4%  0.801(0.629–1.019) 
No. of LNs 22.817<0.001 0.003
 <1058.8%  Reference 
 ≥1072.0%  0.698(0.552–0.882) 

NI: not included in multivariate survival analysis.

N/P LNs ratio: The ratio of the number of negative lymph nodes to the number of metastatic lymph nodes.

*P values refer to the log-rank test of the differences between the two survival curves generated using Kaplan-Meier analysis.

Table 5

Univariate and Multivariate survival analyses for evaluating the number of LNs retrieved influencing RCSS in ypIIIC rectal cancer patients.

Variable5-year CCSUnivariate analysisP*Multivariate analysis
Log rank χ2testHR(95% CI)P
Sex 0.7160.397 NI
 Male40.5%    
 Female45.2%    
Age 7.6150.006 0.010
 <6045.0%  Reference 
 ≥6036.6%  1.383(1.082–1.769) 
Race 1.0010.606 NI
 Caucasian42.4%    
 Black43.0%    
 others37.6%    
Grade 9.7900.007 0.018
 High/ Moderate45.2%  Reference 
 Poor/Anaplastic31.4%  1.470(1.126–1.921) 
 Unknown50.4%  1.083(0.709–1.654) 
 Histotype 0.1490.699 NI
 Adenocarcinoma41.5%    
 Mucinous/signet ring cell43.2%    
ypT Stage 4.3710.037 0.033
 T350.8%  Reference 
 T439.2%  1.428(1.030–1.979) 
ypN Stage 0.6480.421 NI
 ypN142.4%    
 ypN241.7%    
N/P LNs ratio 13.621<0.001 <0.001
 ≦2.3337.3%  Reference 
 >2.3356.1%  0.548(0.394–0.762) 
No. of LNs 13.225<0.001 0.013
 <1032.4%  Reference 
 ≥1046.6%  0.718(0.553–0.933) 

NI: not included in multivariate survival analysis.

N/P LNs ratio: The ratio of the number of negative lymph nodes to the number of metastatic lymph nodes.

*P values refer to the log-rank test of the differences between the two survival curves generated using Kaplan-Meier analysis.

Discussion

The presence of LN metastases in colorectal cancer is well recognized as one of the most important prognostic factors for long-term outcome910. The total number of LNs retrieved is fundamental in most pathological staging systems for colorectal cancer, including the American Joint Committee on Cancer (AJCC), modified Dukes and Astler and Coller. Inadequate LN evaluation is associated with worse outcomes in terms of tumor recurrence and patient survival, particularly in patients with stage II colorectal cancer11121314. The World Congress of Gastroenterology proposed examining a minimum of 12 LNs to classify stage II colorectal tumors15. In the USA, the American Joint Committee on Cancer (AJCC), the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) have also recommended examining at least 12 LNs to assign Stage II rectal disease16. However, debate exists regarding the importance of increased LN harvests in stage III colorectal cancer. Le Voyer et al. showed that for colon cancer patients with N1 stage, there was an absolute 23% improvement in the 5-year overall survival if >40 LNs were analyzed compared with ≤10 LNs (P < 0.001); and in patients with N2 stage, the 5-year overall survival rates following analysis of >35 and <35 LNs were 71% and 51%, respectively (P = 0.002)11. Vather et al. reported that the mean numbers of LNs examined in stage III patients who died or were alive within 5 years was 13.1 vs 14.8, respectively, and this difference was statistically significant (P < 0.001)17. Chen et al. showed that the median survival times for colon cancer patients with 1–7, 8–14 and ≥15 LN retrieval were 46, 52 and 67 months, respectively (P < 0.001)18. However, several studies failed to demonstrate a similar association between survival and LNs harvest in stage III disease13141920. Note that our previous study showed that negative LN count, which does not take positive LN into consideration, was an independent prognostic factor for ypIIIB and ypIIIC rectal cancer patients21. However, the relationship between LN count and RCSS in ypIII rectal cancer has not been fully investigated. In all present guidelines for rectal cancer clinical practice, total LN count is the main concern. Hence, in this study, we mainly focused on the prognostic significance of the total LNs count in patients with rectal cancer treated with preoperative radiotherapy. We first used X-tile to identify 10 as the optimal cutoff value, and then it was confirmed as one of the optimal cutoff numbers in an additional one-by-one cutoff value analysis from 5 to 19. The 5-year RCSS rates of patients with N (cutoff number) or more nodes gradually increased when N ranged from 5 to 9, which suggested that inadequate LN retrieval in LN positive rectal cancer patients may also reflect the failure to remove the involved LNs, particularly in IIIB and IIIC stage patients in our study, thus increasing the risk of local recurrence and distant metastasis. In addition, it may be a marker of poor quality surgical or pathologic care, both of which may cause poor survival. However, a 10 LN cutoff was not an independent prognostic factor in stage IIIA patients. This finding could be explained by the fact that there was a low percentage(3.3%) of T1-T2 patients with more advanced stage than stage IIIA22, therefore, the probability of understaging is significantly low. The intended purpose of preop-RT is tumor down-staging by decreasing the primary tumor bulk and associated LN metastases. Some authors have demonstrated that neoadjuvant therapy may result in radiation-induced lymphocyte destruction and stromal fibrosis resulting in alterations of the morphology of the LNs, making it difficult to detect them2324. Recent research has shown that a decreased number of LNs is related to good tumor response. de Campos-Lobato et al. have shown that retrieving fewer than 12 LNs in the proctectomy specimen of rectal cancer patients treated with preoperative chemoradiation does not affect their overall survival and may be a marker of greater tumor response and, consequently, decreased LR rate25. Rullier et al. were also unable to identify any relationship between a reduced number of LNs examined and decreased patient survival26. Habr-Gama et al. have demonstrated good disease-free survival rates in patients with a complete absence of LNs in their specimens27. We also found that with a cutoff of less than 7, the number of LNs retrieved was not a prognostic factor. Decreased LN retrieval might reflect improved response to preop-RT rather than inappropriate or suboptimal surgical resection in this setting. Most previously published articles determined LN cutoffs considering only a single value, while they barely used one-by-one analysis. In our study, we found that if the cutoff value was greater than 16, the 5-year RCSS rate in patients with a greater number of LNs (i.e., more than the cutoff) would decrease gradually, losing its prognosis value after the number 17(P > 0.05). Several hypotheses could explain this finding. First, the fact that harvesting a higher total number of LNs may result in higher detection rate of metastatic LNs with resultant upstaging of cancer, - a widely accepted concept in surgery; Second, previous study showed that greater LN retrieval could indicate a worse preop-RT response25. On average, 5 more LNs were retrieved from ypN2 stage patients compared with ypN1 stage patients (15 VS 10), and a poorer tumor regression score results in shorter RCSS rates252627. This large population-based study has several potential limitations. First, the SEER database does not include information on the administration of chemotherapy. It is possible that additional or concurrent chemotherapy decreases the number of LNs more than preop-RT alone. Second, individual surgeons, pathologists, and other factors may affect LN harvest, but we cannot adjust for these factors. Finally, SEER database also does not report data on preoperative clinical stage, or tumor regression score, so we cannot analyze the relationship between tumor regression score and LNs retrieval in this study. In conclusion, our analysis of the SEER database revealed that the number of LNs retrieved was a prognostic factor only for numbers ranging from 8 to 16(except for 13) with a maximum χ2 log-rank value of 14.006 at a cutoff of 10. The good tumor response associated with a reduced number of examined LNs may offset the influence of potential under staging with a cutoff of less than 7. Increased LN retrieval (≥17) could indicate worse preop-RT response and poorer RCSS.

Methods

Patient selection in the SEER database

Data from the Surveillance Epidemiology and End Results (SEER) Program of the United States National Cancer Institute, release 2015, were utilized for this study. SEER, a population-based cancer registry, collects cancer incidence and survival data from 18 regional population-based registries covering approximately 26% of the US population. The SEER data contain no identifiers and are publicly available for studies of cancer-based epidemiology and TNM staging of colorectal2228, gastric29, esophageal cancer30 and other cancers. SEER registry patients eligible for this cohort included those with adenocarcinoma, NOS (8150/3), adenocarcinoma in adenomatous polyps (8210/3), villous adenoma (8261/3) or tubulovillous adenoma (8263/3), mucinous adenocarcinoma (8480/3), signet ring cell carcinoma (8490/3) of the rectum diagnosed from 1998 through 2005 and treated with surgical resection. The inclusive study dates were chosen to allow a known treatment sequence of “radiation prior to surgery”. The patient age was limited to 18 to 80 years old. Patients diagnosed after 2006 were excluded to ensure adequate follow-up times. Additional exclusion criteria were as follows: no LNs examined pathologically, ypN0 patients, with synchronous distance metastases, and patients who died within 30 postoperative days. The following information was retrieved from the SEER database: the patient age, sex, race, extension of primary tumor invasion, radiation sequence, total number of LNs examined, number of involved LNs, grade, survival time, and SEER cause-specific death classification. All cases were restaged based on the AJCC-7 staging. The primary endpoint of the study is RCSS which was calculated from the date of diagnosis to the date of cancer specific death. Deaths attributed to the cancer of interest are treated as events and deaths from other causes are treated as censored observation.

Statistical analysis

The LNs cutoff points were analyzed using the X-tile program (http://www.tissuearray.org/rimmlab/), which identified the cutoff with the minimum P values from log-rank χ statistics for the categorical LNs in terms of survival31. The relationship between various clinical and histological variables and survival was evaluated using the Kaplan-Meier method. Differences between survival curves were tested for statistical significance by using log rank test. The Cox proportional hazard regression model was used to identify the variables that could independently influence survival in preop-RT rectal cancer patients. The Mann-Whitney U test was used for continuous variables, and the chi-square test was used for categorical variables. The 5-year RCSS rate was estimated from Kaplan-Meier curves. Deaths attributed to the rectal cancer of interest are treated as events and deaths from other causes are treated as censored observation. Statistical analyses were performed with the statistical software package SPSS (Statistical Package for the Social Sciences) for Windows, version 17 (SPSS Inc, Chicago, IL, USA). Two-sided p values of less than 0.05 were considered to be statistically significant.

Additional Information

How to cite this article: Li, Q. et al. Effect of Lymph Node Count on Pathological Stage III Rectal Cancer with Preoperative Radiotherapy. Sci. Rep. 5, 16990; doi: 10.1038/srep16990 (2015).
  31 in total

1.  Number of lymph node metastases is better predictor of prognosis than level of lymph node metastasis in patients with node-positive colon cancer.

Authors:  On Suzuki; Yoshiaki Sekishita; Tuneo Shiono; Koichi Ono; Masaru Fujimori; Satoshi Kondo
Journal:  J Am Coll Surg       Date:  2006-05       Impact factor: 6.113

Review 2.  Excavation of a buried treasure--DNA, mRNA, miRNA and protein analysis in formalin fixed, paraffin embedded tissues.

Authors:  R Klopfleisch; A T A Weiss; A D Gruber
Journal:  Histol Histopathol       Date:  2011-06       Impact factor: 2.303

3.  More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study.

Authors:  Steven L Chen; Anton J Bilchik
Journal:  Ann Surg       Date:  2006-10       Impact factor: 12.969

4.  Lymph node ratio as determined by the 7th edition of the American Joint Committee on Cancer staging system predicts survival in stage III colon cancer.

Authors:  Kwang Dae Hong; Sun Il Lee; Hong Young Moon
Journal:  J Surg Oncol       Date:  2010-12-22       Impact factor: 3.454

5.  How does the number of resected lymph nodes influence TNM staging and prognosis for esophageal carcinoma?

Authors:  Yang Hu; Chunyan Hu; Helin Zhang; Yumin Ping; Long-Qi Chen
Journal:  Ann Surg Oncol       Date:  2009-12-02       Impact factor: 5.344

6.  Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes.

Authors:  Leonard L Gunderson; John Milburn Jessup; Daniel J Sargent; Frederick L Greene; Andrew Stewart
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

7.  Revised TN categorization for colon cancer based on national survival outcomes data.

Authors:  Leonard L Gunderson; John Milburn Jessup; Daniel J Sargent; Frederick L Greene; Andrew K Stewart
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

8.  Prognostic implications of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy.

Authors:  Tobias Leibold; Jinru Shia; Leyo Ruo; Bruce D Minsky; Timothy Akhurst; Marc J Gollub; Michelle S Ginsberg; Steven Larson; Elyn Riedel; W Douglas Wong; José G Guillem
Journal:  J Clin Oncol       Date:  2008-03-24       Impact factor: 44.544

9.  Lymph node examination as a predictor of long-term outcome in Dukes B colon cancer.

Authors:  Ryash Vather; Tarik Sammour; Kamran Zargar-Shoshtari; Patricia Metcalf; Andrew Connolly; Andrew Hill
Journal:  Int J Colorectal Dis       Date:  2008-08-21       Impact factor: 2.571

10.  Absence of lymph nodes in the resected specimen after radical surgery for distal rectal cancer and neoadjuvant chemoradiation therapy: what does it mean?

Authors:  Angelita Habr-Gama; Rodrigo O Perez; Igor Proscurshim; Viviane Rawet; Diego D Pereira; Afonso H S Sousa; Desiderio Kiss; Ivan Cecconello
Journal:  Dis Colon Rectum       Date:  2008-03       Impact factor: 4.585

View more
  7 in total

1.  The prognostic value of lymph nodes count on survival of patients with node-negative gastric cancer.

Authors:  Wei-Feng Zheng; Ting-Ting Ji; Yong Lin; Rong-Zhou Li
Journal:  Oncotarget       Date:  2016-07-12

2.  The prognostic value of negative lymph node count for patients with gastric cancer who received preoperative radiotherapy.

Authors:  Xinxing Li; Weigang Zhang; Xianwen Zhang; Haolu Wang; Kai Xu; Houshan Yao; Jun Yao; Xiaowen Liang; Zhiqian Hu
Journal:  Oncotarget       Date:  2017-07-18

3.  Negative lymph node count is an independent prognostic factor for patients with rectal cancer who received preoperative radiotherapy.

Authors:  Xinxing Li; Hao Lu; Kai Xu; Haolu Wang; Xiaowen Liang; Zhiqian Hu
Journal:  BMC Cancer       Date:  2017-03-28       Impact factor: 4.430

4.  Adjuvant radiotherapy improves cause specific survival in stage II, not stage III mucinous carcinoma of the rectum.

Authors:  Qingguo Li; Yaqi Li; Weixing Dai; Sheng Wang; Ye Xu; Xinxiang Li; Sanjun Cai
Journal:  BMC Cancer       Date:  2017-01-26       Impact factor: 4.430

5.  Lymph node status as a prognostic factor after palliative resection of primary tumor for patients with metastatic colorectal cancer.

Authors:  Qingguo Li; Changjian Wang; Yaqi Li; Xinxiang Li; Ye Xu; Guoxiang Cai; Peng Lian; Sanjun Cai
Journal:  Oncotarget       Date:  2017-07-18

6.  Negative lymph node count is a significant prognostic factor in patient with stage IV gastric cancer after palliative gastrectomy.

Authors:  Changhua Zhuo; Mingang Ying; Ruirong Lin; Xianyi Wu; Shen Guan; Chunkang Yang
Journal:  Oncotarget       Date:  2017-04-26

7.  Nomograms incorporated serum direct bilirubin level for predicting prognosis in stages II and III colorectal cancer after radical resection.

Authors:  Qunfeng Zhang; Xiaowei Ma; Qunhuan Xu; Juanxiu Qin; Yanhua Wang; Qian Liu; Hua Wang; Min Li
Journal:  Oncotarget       Date:  2016-08-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.